Claims for Patent: 8,105,794

Summary for Patent: 8,105,794

Title:	Rapid nasal assay kit
Abstract:	The present invention relates to an assay which can be used on nasal secretions. The assay is used to determine the cause of nasal secretions, for example whether the secretions are due to an allergic reaction or a non-allergic reaction.
Inventor(s):	Shaari; Christopher (Demarest, NJ)
Assignee:	Toxcure LLC (Hackensack, NJ)
Application Number:	13/021,308
Patent Claims:	1. A nasal secretion assay kit comprising: a. a nasal secretion gathering means; and b. a reagent which contains one or more substances which will react with a substance in the nasal secretion to determine whether said nasal secretion is caused by an allergic reaction or a non-allergic reaction. 2. The nasal secretion assay kit of claim 1, wherein the substance in the nasal secretion is selected from the group consisting of IL4, IL13, histamine, LTC4, LTD4, LTE4, elestase, T2 lymphocytes, IgE, EG2, CCR4, CCR8 and CCR3; wherein a positive reaction is indicative of allergic rhinitis. 3. The nasal secretion assay kit of claim 2, wherein the reagent is a sandwich ELISA comprising: a. a capture antibody which will react with the substance in the nasal secretion to form a complex, and b. a detection antibody which will react with the capture antibody and substance complex. 4. The rapid nasal assay kit of claim 1, wherein the nasal secretion gathering means comprises: a. an absorbant material which fits into a nasal vestibule; and b. an atomizing or aerosoling device comprising a container and a tube, wherein the tube passes through the absorbant material such that when the container is contracted, its contents pass through the tube and irrigates the nose and sinuses, and the contents are then absorbed onto the absorbant material. 5. The rapid nasal assay kit of claim 1, wherein the reagent is: a. a capture antibody, which will react with and forms a complex with a capture substance in the nasal secretion, wherein the capture substance is selected from the group consisting of TH2 cells, IL4, IL13, ILI-B, exotoxin, CCR4, CCR8, CCR3, histamine, leukocytes, EG2 and IgE; and b. a detection antibody, which will react with the complex and will generate a detectable response if the complex is present; wherein the presence of a detectable response indicates that a nasal secretion is the result of allergic rhinitis. 6. The rapid nasal assay kit of claim 1, wherein the nasal secretion gathering means is paper, tissue, or cloth. 7. The rapid nasal assay kit of claim 5, wherein the nasal secretion gathering means comprises a sponge, which can fit into a nostril, an atomizing/aerosoling device, which passes through the sponge with a first end in communication with a sinus cavity, which is above the sponge, and a container attached to a second end of the atomizing/aerosoling device, wherein said container can contain a liquid. 8. The rapid nasal assay kit of claim 5, wherein the capture antibody is contained on the nasal secretion gathering means. 9. The rapid nasal assay kit of claim 5, wherein the detection antibody is contained on the nasal secretion gathering means. 10. The rapid nasal assay kit of claim 8, wherein the detection antibody is contained on the nasal secretion gathering means. 11. The rapid nasal assay kit of claim 5, wherein the detection antibody, which has reacted with the complex, generates a detectable response because the detection antibody is labeled. 12. The rapid nasal assay kit of claim 11, wherein the detection antibody is labeled prior to the reaction of the detection antibody with the complex. 13. The rapid nasal assay kit of claim 11, wherein the detection antibody is labeled after the detection antibody reacts with the complex. 14. The rapid nasal assay kit of claim 1, wherein the reagent is: a. a capture antibody, which will react with and form a complex with a capture substance selected from the group consisting of THI cells, INF-Garnrna, CCR5 and CXCR3; and b. a detection antibody, which will react with the complex and will generate a detectable response if the complex is present; wherein the presence of a detectable response indicates that a nasal secretion is the result of non-allergic rhinitis. 15. The rapid nasal assay kit of claim 1, wherein the reagent is: a. a first capture antibody, which will react with and form a first complex with a first capture substance in the nasal secretion, wherein the first capture substance is selected from the group consisting of TH2 cells, IL4, IL13, IL1-B, exotoxin, CCR4, CCR8, CCR3, histamine, leukocytes, LTC4, LTD4, LTE4, elestase, T2 lymphocytes, EG2 and IgE; and b. a first detection antibody, which will react with the first complex and will generate a first detectable response if the complex is present; c. a second capture antibody, which will react with and form a second complex with a second capture substance in the nasal secretion, wherein the second capture substance is selected from the group consisting of TH1 cells, INF-Gamma, CCR5 and CXCR3; and d. a second detection antibody, which will react with the second complex and will generate a second detectable response if the second complex is present; wherein the first detectable response is distinguishable from the second detectable response; and i. a first detectable response and no second detectable response indicates that a nasal secretion is the result of allergic rhinitis; ii. a second detectable response and no first detectable response indicates that a nasal secretion is the result of non-allergic rhinitis; and iii. a first detectable response and a second detectable response indicates that a nasal secretion is the result of allergic rhinitis and non-allergic rhinitis. 16. The nasal secretion assay kit of claim 2, wherein the allergic rhinitis is selected from the group consisting of: seasonal, perennial, episodic, and occupational. 17. The nasal secretion assay kit of claim 1, wherein the capture substance is INF-Gamma.

Details for Patent 8,105,794

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2026-02-07